Illumina appointed Daniel M. Skovronsky, MD, PhD, to its board of directors, effective June 16, 2026.
Skovronsky is chief scientific and product officer of Eli Lilly and president of Lilly Research Laboratories, where he leads Lilly’s global research and development organization and oversees commercial products in cardiometabolic health, immunology, and neuroscience. He joined Lilly in 2010 after Lilly acquired Avid Radiopharmaceuticals, the company he founded in 2004 and led as chief executive. He also previously served on the board of Myriad Genetics.
The appointment adds a director with experience in drug discovery, clinical development, and translational medicine. Illumina said that background is relevant to its genomics and multiomics platforms. The company said Skovronsky’s experience building and advancing large research portfolios could support its work in innovation across genomics, multiomics, and precision medicine.
Skovronsky earned a bachelor’s degree in molecular biophysics and biochemistry from Yale University and both an MD and PhD from the University of Pennsylvania, followed by residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. As a result of these announcements, the company's shares have moved 2.13% on the market, and are now trading at a price of $164.82. Check out the company's full 8-K submission here.
